Zobrazeno 1 - 10
of 1 065
pro vyhledávání: '"Valent, J."'
Autor:
Dima D; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA., Hughes M; Department of Hematology-Oncology, Columbia University, New York, NY, USA., Orland M; Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA., Ullah F; Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA., Goel U; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA., Anwer F; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA., Raza S; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA., Mazzoni S; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA., Bhutani D; Department of Hematology-Oncology, Columbia University, New York, NY, USA., Williams L; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA., Lentzsch S; Department of Hematology-Oncology, Columbia University, New York, NY, USA., Samaras C; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA., Valent J; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA., Chakraborty R; Department of Hematology-Oncology, Columbia University, New York, NY, USA., Khouri J; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
Publikováno v:
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis [Amyloid] 2024 Sep; Vol. 31 (3), pp. 195-201. Date of Electronic Publication: 2024 Jul 02.
Autor:
Gasoyan H; Center for Value-Based Care Research, Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, OH, USA. gasoyah@ccf.org.; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA. gasoyah@ccf.org., Anwer F; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Kovach JD; Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA., Casacchia NJ; Center for Value-Based Care Research, Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, OH, USA., Wang M; Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Valent J; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Halpern MT; Healthcare Delivery Research Program, National Cancer Institute, Bethesda, MD, USA., Rothberg MB; Center for Value-Based Care Research, Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, OH, USA.; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
Publikováno v:
Blood cancer journal [Blood Cancer J] 2024 Aug 23; Vol. 14 (1), pp. 142. Date of Electronic Publication: 2024 Aug 23.
Autor:
Dima D; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA.; University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Goel U; Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA., Sannareddy A; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Ibeh N; Department of Pathology and Laboratory Medicine, University of Texas, Houston, Texas, USA., Ullah F; Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA., Afrough A; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Mazzoni S; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA., Mehdi A; Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio, USA., Rudoni J; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA., Raza S; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA., De Simone N; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Williams L; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA., Khan A; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Rashid A; Department of Internal Medicine, University of Kansas, Kansas City, Kansas, USA., Rice M; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA., Ricci K; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA., Samaras C; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA., Valent J; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA., Anderson LD Jr; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Anwer F; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA., Kaur G; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Khouri J; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA.
Publikováno v:
Hematological oncology [Hematol Oncol] 2024 Jul; Vol. 42 (4), pp. e3293.
Autor:
Samala RV; Department of Palliative and Supportive Care, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Ave. CA-53, Cleveland, OH, 44195, USA. samalar@ccf.org., Nurse DP; Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA., Chen X; Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA., Wei W; Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA., Crook JJ; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Fada SD; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Valent J; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2024 Jun 27; Vol. 32 (7), pp. 468. Date of Electronic Publication: 2024 Jun 27.
Autor:
Lin CH; Department of Internal Medicine, Case Western Reserve University, MetroHealth Campus, Cleveland, OH 44109, USA., Tariq MJ; Department of Hematology-Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA., Ullah F; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA., Sannareddy A; Department of Hematology-Oncology, UT Southwestern, Dallas, TX 75235, USA., Khalid F; Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA., Abbas H; Medical College of Wisconsin, Milwaukee, WI 53226, USA., Bader A; School of Medicine, University of Missouri-Kansas City, Kansas City, MO 64110, USA., Samaras C; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA., Valent J; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA., Khouri J; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA., Anwer F; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA., Raza S; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA., Dima D; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA.; Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109, USA.
Publikováno v:
International journal of molecular sciences [Int J Mol Sci] 2024 Jun 04; Vol. 25 (11). Date of Electronic Publication: 2024 Jun 04.
Autor:
Gasoyan H; Department of Internal Medicine and Geriatrics, Center for Value-Based Care Research, Primary Care Institute, Cleveland Clinic, Cleveland, OH.; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH., Anwer F; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH., Casacchia NJ; Department of Internal Medicine and Geriatrics, Center for Value-Based Care Research, Primary Care Institute, Cleveland Clinic, Cleveland, OH., Kovach JD; Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH., Valent J; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH., Wang M; Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH., Halpern MT; Healthcare Delivery Research Program, National Cancer Institute, Bethesda, MD., Rothberg MB; Department of Internal Medicine and Geriatrics, Center for Value-Based Care Research, Primary Care Institute, Cleveland Clinic, Cleveland, OH.; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.
Publikováno v:
JCO oncology practice [JCO Oncol Pract] 2024 May; Vol. 20 (5), pp. 699-707. Date of Electronic Publication: 2024 Feb 14.
Autor:
Davis JA; US Myeloma Innovations Research Collaborative, Kansas City, Kansas; Department of Hematology-Oncology, Medical University of South Carolina, Charleston, South Carolina., Dima D; US Myeloma Innovations Research Collaborative, Kansas City, Kansas; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Center, Cleveland, Ohio., Ahmed N; US Myeloma Innovations Research Collaborative, Kansas City, Kansas; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas., DeJarnette S; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas., McGuirk J; US Myeloma Innovations Research Collaborative, Kansas City, Kansas; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas., Jia X; Department of Biostatistics and Quantitative Health Science, Cleveland Clinic, Cleveland, Ohio., Raza S; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Center, Cleveland, Ohio., Khouri J; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Center, Cleveland, Ohio., Valent J; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Center, Cleveland, Ohio., Anwer F; US Myeloma Innovations Research Collaborative, Kansas City, Kansas; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Center, Cleveland, Ohio., Abdallah AO; US Myeloma Innovations Research Collaborative, Kansas City, Kansas; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas., Hashmi H; US Myeloma Innovations Research Collaborative, Kansas City, Kansas; Department of Hematology-Oncology, Medical University of South Carolina, Charleston, South Carolina. Electronic address: hashmih@musc.edu.
Publikováno v:
Transplantation and cellular therapy [Transplant Cell Ther] 2024 Mar; Vol. 30 (3), pp. 298-305. Date of Electronic Publication: 2023 Dec 22.
Autor:
Dima D; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio; US Myeloma Innovations Research Collaborative, Westwood, Kansas. Electronic address: dimad@ccf.org., Davis JA; US Myeloma Innovations Research Collaborative, Westwood, Kansas; Division of Hematology/Oncology, Medical University of South Carolina, Charleston, South Carolina., Ahmed N; US Myeloma Innovations Research Collaborative, Westwood, Kansas; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas., Jia X; Department of Biostatistics and Quantitative Health Science, Cleveland Clinic, Cleveland, Ohio., Sannareddy A; Division of Hematologic Malignancies and Cellular Therapy, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas., Shaikh H; US Myeloma Innovations Research Collaborative, Westwood, Kansas; Division of Hematology, Oncology and Blood & Marrow Transplantation, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa., Shune L; US Myeloma Innovations Research Collaborative, Westwood, Kansas; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas., Kaur G; Division of Hematologic Malignancies and Cellular Therapy, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas., Khouri J; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio; US Myeloma Innovations Research Collaborative, Westwood, Kansas., Afrough A; US Myeloma Innovations Research Collaborative, Westwood, Kansas; Division of Hematologic Malignancies and Cellular Therapy, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas., Strouse C; US Myeloma Innovations Research Collaborative, Westwood, Kansas; Division of Hematology, Oncology and Blood & Marrow Transplantation, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa., Lochner J; Division of Hematology, Oncology and Blood & Marrow Transplantation, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa., Mahmoudjafari Z; US Myeloma Innovations Research Collaborative, Westwood, Kansas; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas., Raza S; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio; US Myeloma Innovations Research Collaborative, Westwood, Kansas., Valent J; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio., Anderson LD Jr; Division of Hematologic Malignancies and Cellular Therapy, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas., Anwer F; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio; US Myeloma Innovations Research Collaborative, Westwood, Kansas., Abdallah AO; US Myeloma Innovations Research Collaborative, Westwood, Kansas; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas., Hashmi H; US Myeloma Innovations Research Collaborative, Westwood, Kansas; Division of Hematology/Oncology, Medical University of South Carolina, Charleston, South Carolina; Division of Hematology/Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
Publikováno v:
Transplantation and cellular therapy [Transplant Cell Ther] 2024 Mar; Vol. 30 (3), pp. 308.e1-308.e13. Date of Electronic Publication: 2023 Dec 26.
Publikováno v:
Blood and Lymphatic Cancer: Targets and Therapy, Vol 2016, Iss Issue 1, Pp 21-35 (2016)
Beth Faiman, Jason Valent Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA Abstract: Improved understanding as to the biology of multiple myeloma (MM) and the bone marrow microenvir
Externí odkaz:
https://doaj.org/article/0849c85822d74002822d0eaab3b3a1d7
Autor:
Kumar SK; Mayo Clinic Comprehensive Cancer Center., Callander NS; University of Wisconsin Carbone Cancer Center., Adekola K; Robert H. Lurie Comprehensive Cancer Center of Northwestern University., Anderson LD Jr; UT Southwestern Simmons Comprehensive Cancer Center., Baljevic M; Vanderbilt-Ingram Cancer Center., Baz R; Moffitt Cancer Center., Campagnaro E; University of Michigan Rogel Cancer Center., Castillo JJ; Dana-Farber/Brigham and Women's Cancer Center., Costello C; UC San Diego Moores Cancer Center., D'Angelo C; Fred & Pamela Buffett Cancer Center., Derman B; The UChicago Medicine Comprehensive Cancer Center., Devarakonda S; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute., Elsedawy N; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center., Garfall A; Abramson Cancer Center at the University of Pennsylvania., Godby K; O'Neal Comprehensive Cancer Center at UAB., Hillengass J; Roswell Park Comprehensive Cancer Center., Holmberg L; Fred Hutchinson Cancer Center., Htut M; City of Hope National Medical Center., Huff CA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins., Hultcrantz M; Memorial Sloan Kettering Cancer Center., Kang Y; Duke Cancer Institute., Larson S; UCLA Jonsson Comprehensive Cancer Center., Lee H; The University of Texas MD Anderson Cancer Center., Liedtke M; Stanford Cancer Institute., Martin T; UCSF Helen Diller Family Comprehensive Cancer Center., Omel J; Patient Advocate., Robinson T; Yale Cancer Center/Smilow Cancer Hospital., Rosenberg A; UC Davis Comprehensive Cancer Center., Sborov D; Huntsman Cancer Institute at the University of Utah., Schroeder MA; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine., Sherbenou D; University of Colorado Cancer Center., Suvannasankha A; Indiana University Melvin and Bren Simon Comprehensive Cancer Center., Valent J; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute., Varshavsky-Yanovsky AN; Fox Chase Cancer Center., Snedeker J; National Comprehensive Cancer Network., Kumar R; National Comprehensive Cancer Network.
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2024 Jan; Vol. 22 (1D), pp. e240001.